The Effect of Gait Training Using Different Slope Types on Balance in COPD Patients
Condition(s) studied
Investigational drug(s) / intervention(s)
Level walking training: For 8 weeks, level walking training will be done 2 times a week at a slope of 0 degrees.
Downhill walking training: For 8 weeks, downhill walking training will be done 2 times a week at a slope of -10 degrees.
Uphill walking training: For 8 weeks, uphill walking training will be done 2 times a week at a slope of +10 degrees.
Study summary
Although COPD is basically a respiratory system disease, its effects are not limited to the respiratory system. In this context, one parameter affected in COPD patients is balance. Recent studies have highlighted the importance of assessing balance and incorporating it into treatment options such as pulmonary rehabilitation. In this context, we aim to diversify the training by using different slope types (downhill, level, uphill) in aerobic exercise training, which is a strong component of pulmonary rehabilitation, and to evaluate the effect of slope type on balance. Testing different types of inclines in aerobic exercise training has the potential to result in different muscular gains. We anticipate that this may result in different balance gains.
Eligibility
Primary outcome measure(s)
- Postural stability test — Up to 8 weeks.
The test reflects a person's ability to maintain the center of balance. - Limits of Stability (LOS) Test — Up to 8 weeks.
The maximum vertical angle that the body can reach while standing without losing balance is called the stability limit. - Clinical Test of Sensory Integration of Balance (CTSIB) — Up to 8 weeks.
The test assesses how well the person can integrate sensory input to maintain balance.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Bezmialem Vakif University, Department of Physiotherapy and Rehabilitation | Istanbul | Eyüp Sultan | Recruiting |
More Acibadem University trials in Turkey
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06644898 on ClinicalTrials.gov ↗ ← All trials in Turkey